Jim Cramer
Jim Cramer talks about his ‘favorite stock,’ telling investors to buy some as we did last week
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1. U.S. stocks rose Monday, though they’re still having a rough August. Nvidia (NVDA), which has been slumping recently, jumped about 5.5% to start the week. Morgan Stanley reiterated Nvidia […]
Read More
We’re optimistic about this struggling entertainment stock despite an expected weak quarter
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. Back-to-back losses Still believe in Disney Eli Lilly keeps going 1. Back-to-back losses U.S. stocks on Wednesday were sinking for the second straight session ahead of this week’s key inflation […]
Read More
Here’s what is behind the stock market’s selloff and what we’re doing about it
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. Stocks sink Eli Lilly surges Palo Alto slumps 1. Stocks sink U.S. stocks tumbled Tuesday after Moody’s downgraded the credit rating on a slew of small and mid-sized banks, sending […]
Read More
Here are the 5 price-target changes and 4 trades we made during this busy earnings week
In a jam-packed week of earnings, the Club executed multiple trades and elevated price targets for some of our biggest stocks. Many of these moves stemmed from what we saw in quarterly numbers and heard on conference calls. Here’s a day-by-day look at the portfolio action. Monday The week began with our decision to exit […]
Read More
Troubled health name bounces after strong quarter and guidance. Here’s our view on the stock
Troubled Club holding Bausch Health Companies (BHC) reported better-than-expected quarterly results before the bell Thursday. However, it’s not nearly enough to get this stock out of the penalty box. Sales in the second quarter rose 10% to $2.17 billion, exceeding expectations of $2.04 billion, according to estimates compiled by Refinitiv. (On an organic basis — […]
Read More
Humana calms Wall Street’s jitters with quarterly results, clearing way for stock to run higher
Humana (HUM) reported second-quarter results Wednesday that were much better than feared, sending its stock price soaring and giving us the confidence to stick with the jilted health insurer. Revenue for the three months ended June 30 rose 13% year-over-year, to $26.75 billion, exceeding analysts’ estimates of $26.23 billion, according to Refinitiv. Adjusted earnings-per-share (EPS) […]
Read More
We’re exiting a health-care name — putting us on the hunt to buy a new stock for the portfolio
We’re taking a hard look at the Bullpen and the rest of the market for new opportunities. Source
Read More
The Fed could be about to crash the airplane, but the concentrate should really be on income
Consider the role of the strategist in modern day-day portfolio administration. Her principal intention is to figure out if the Federal Reserve is likely to end elevating curiosity rates . She has to check out to figure out why the lengthier close of the yield curve is predicting a recession. Supplied what the generate is […]
Read More
Why Cramer thinks this retailer is the ‘ultimate trade-down play’
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. Health care in focus ‘Ultimate trade-down play’ Watch the Bullpen 1. Health care in focus Club holdings Danaher (DHR) and GE Healthcare (GEHC) reported better-than-expected earnings before the bell Tuesday. […]
Read More
Here’s what Jim Cramer thinks about J&J stock after a pivotal talc case verdict
A closely watched talc trial in California goes against Johnson & Johnson (JNJ), adding uncertainty around whether tens of thousands of other plaintiffs suing the company will sign on to J & J’s proposed $8.9 billion settlement offer or seek to get their own days in court. Jim Cramer believes the biopharmaceutical company was “too […]
Read More